8-K: Accelerate Diagnostics Reports Mixed 2023 Results, Advances Wave System Development

Accelerate Diagnostics announced its fourth quarter and full-year 2023 financial results, highlighting progress in its next-generation rapid antibiotic susceptibility testing system, Accelerate Wave, while facing revenue and margin challenges.

Summary

• Accelerate Diagnostics reported net sales of $3.0 million for the fourth quarter of 2023, consistent with the same period in the prior year, and $12.1 million for the full year, down from $12.8 million in the prior year.
• The company's gross margin for the quarter was approximately 21%, down from 28% in the same quarter of the prior year, and 21% for the full year, down from 26% in the prior year, primarily due to inflation and a $1.2 million inventory write-down.
• Selling, general, and administrative (SG&A) costs decreased to $5.8 million for the quarter and $31.2 million for the year, compared to $8.8 million and $39.2 million respectively in the prior year, due to lower employee-related expenses.
• Research and development (R&D) costs were $5.6 million for the quarter and $25.4 million for the year, compared to $6.0 million and $26.9 million respectively in the prior year, due to lower employee and third-party development costs.
• The net loss for the quarter was $13.0 million, or $0.89 per share, and $61.6 million, or $4.94 per share, for the full year.
• Cash used in the fourth quarter was $7.9 million, and $46.3 million for the full year, which includes approximately $8 million of debt restructuring related expenses.
• The company ended the year with $13.2 million in cash, investments, and cash equivalents.
• Accelerate Diagnostics is progressing with the development of its Accelerate Wave system, with clinical trials expected to begin in the second quarter of 2024 and FDA submission anticipated by the end of the third quarter of 2024.
• The company has completed the 510(k) application for the Accelerate Arc system and anticipates FDA submission during the first quarter of 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there is positive progress in product development, the financial results are concerning with declining revenue, gross margin, and significant losses. The company is making progress on cost cutting and has a promising product pipeline, but the financial challenges are a significant concern.

Positives

• The Accelerate Wave system development is complete and has demonstrated impressive time-to-results.
• Customer interest in the Wave system is high, with 90% expressing interest in adoption.
• The company has secured multi-year contracts with a significant portion of its U.S. Pheno customers.
• SG&A and R&D expenses have decreased due to cost-cutting measures.
• Cash burn has been reduced in the second half of 2023.
• The company has submitted the 510(k) application for the Arc system.
• The company is in discussions with potential strategic partners for the commercialization of Wave.

Negatives

• Net sales for the full year decreased compared to the prior year.
• Gross margin declined due to inflation and an inventory write-down.
• The company experienced a significant net loss for both the quarter and the full year.
• Cash used for the year was substantial, including debt restructuring expenses.
• Instrument sales decreased by 11% in the quarter compared to the same quarter of the prior year.
• The company's cash position has decreased significantly year over year.

Risks

• The company faces challenges in resolving its financial condition and obtaining additional capital.
• There are risks associated with obtaining regulatory approvals for its products.
• The company's ability to commercialize its products successfully is uncertain.
• The company is subject to volatility in the global economy and supply chain.
• There is a risk of less than expected operating and financial benefits from cost-cutting measures.
• The strategic selling process for rapid AST is complex and involves multiple stakeholders.

Future Outlook

The company anticipates beginning clinical trials for the Accelerate Wave system in the second quarter of 2024, with FDA submission expected by the end of the third quarter of 2024. They also expect to sign a strategic partnership for Wave by mid-year. The company is focused on reducing cash burn and expects to see further reductions in 2024.

Management Comments

• Jack Phillips, President and CEO, stated that the company made significant progress with the development of the Accelerate Wave system and believes they remain on plan to begin clinical trials in the second quarter of 2024.
• Jack Phillips commented that the Accelerate Wave is anticipated to set the new standard for rapid, same-shift, susceptibility testing.
• David Patience, CFO, highlighted the reduction in cash burn in the second half of 2023 and the focus on further reductions moving forward.
• Jack Phillips mentioned that the company is confident in signing a strategic partnership by mid-year for the commercialization of Wave.
• Jack Phillips stated that the company has completed and submitted its 510(k) application for the Arc instrument and consumable.

Industry Context

The announcement comes amid a growing need for rapid and accurate diagnostic solutions for antibiotic resistance and sepsis. The company's focus on developing the Accelerate Wave system aligns with the industry trend towards faster and more efficient susceptibility testing methods. The company is competing with other diagnostic companies in the microbiology space, and the success of Wave will be crucial for its future growth.

Comparison to Industry Standards

• The Accelerate Pheno system is positioned as a solution that offers results 1-2 days faster than existing methods, which is a significant advantage in the rapid diagnostics market.
• The Accelerate Wave system is designed to provide same-shift results, which is a significant improvement over traditional methods that can take 8-24 hours for isolate results.
• The company's claim that Wave can make definitive calls for Pseudomonas aeruginosa in under 4.5 hours is notable, as this bacteria is known to be slow-growing and difficult to test.
• The company is competing with established players in the microbiology diagnostics market, such as bioMérieux and BD, as well as emerging companies developing rapid AST platforms.
• The company's partnership with Bruker for the Arc system leverages Bruker's existing MALDI technology, which is widely used in clinical microbiology labs.

Stakeholder Impact

• Shareholders are impacted by the company's financial losses and declining stock price.
• Employees are impacted by cost-cutting measures and potential restructuring.
• Customers are impacted by the potential for new and improved diagnostic solutions.
• Suppliers are impacted by the company's financial condition and ability to pay.
• Creditors are impacted by the company's debt and ability to repay.

Next Steps

• Complete preclinical trials for the Accelerate Wave system by the end of April 2024.
• Begin clinical trials for the Accelerate Wave system in the second quarter of 2024.
• Submit the Accelerate Wave system for FDA approval by the end of the third quarter of 2024.
• Continue discussions with potential strategic partners for the commercialization of Wave.
• Continue to reduce cash burn and operating expenses.
• Launch the Accelerate Arc system in the US after FDA approval.

Key Dates

Keywords

Antibiotic Susceptibility Testing, Rapid Diagnostics, Accelerate Wave, Accelerate Pheno, Accelerate Arc, Microbiology, In Vitro Diagnostics, FDA Approval, Sepsis, Antimicrobial Resistance